Mural Oncology Reports $3.7 Million Net Loss and Significant Organizational Changes

Mural Oncology plc reported significant financial challenges in its latest 10-Q filing for the quarter ending September 30, 2025. The company recorded a net loss of $3.7 million for the quarter, a notable decrease from a loss of $31.8 million in the same period last year. For the nine months ending September 30, 2025, the total net loss was $84.8 million, compared to $94.2 million for the same period in 2024. The reduction in losses is attributed to a substantial decrease in research and development expenses, which fell to $4.3 million from $27.6 million year-over-year, primarily due to the cessation of clinical development activities related to its lead product candidate, nemvaleukin alfa.

The company’s total assets decreased significantly to $65.8 million as of September 30, 2025, down from $169.4 million at the end of 2024. This decline was largely driven by a reduction in cash and cash equivalents, which fell to $58.9 million from $115.5 million. Mural's liabilities also decreased, with total liabilities at $10.6 million compared to $28.9 million at the end of the previous fiscal year. The company’s accumulated deficit increased to $244.2 million, reflecting ongoing operational losses and the impact of restructuring efforts.

Strategically, Mural Oncology has undergone significant organizational changes, including a workforce reduction of approximately 90% and the discontinuation of all clinical development of nemvaleukin. This decision followed the failure of the Phase 3 ARTISTRY-7 trial to meet its primary endpoint. In August 2025, Mural entered into a Transaction Agreement with XOMA Royalty Corporation for an acquisition, which was approved by shareholders on October 24, 2025. The acquisition is expected to close in the fourth quarter of 2025, subject to certain conditions.

Operationally, Mural has ceased all remaining development activities and is exploring strategic alternatives to maximize shareholder value. The company has not generated any revenue from product sales and does not anticipate doing so in the near future. As of September 30, 2025, Mural had no products approved for commercial sale, and its future financial performance remains uncertain. The company has indicated that it will need to raise additional funding to advance any product candidates, which may not be available on acceptable terms.

Looking ahead, Mural Oncology faces substantial doubt about its ability to continue as a going concern. The company’s existing cash reserves are not sufficient to resume preclinical or clinical development of any product candidates while meeting its obligations. If the acquisition does not close or if additional funding is not secured, Mural may have to consider dissolution and liquidation as potential outcomes. The company’s management has emphasized the need for strategic transactions to ensure its viability moving forward.